25 January 2026 in Brazilian Journal of Oncology
Breast cancer is the leading cause of cancer-related deaths among women in Brazil, highlighting the importance of early detection to improve outcomes. Artificial intelligence (AI) has garnered considerable attention for its potential to enhance breast cancer screening by reducing unnecessary exams, minimizing diagnostic errors, and increasing efficiency and accuracy—exemplified by advanced tools like Mirai. The present retrospective study analyzed 1,000 patients who underwent bilateral mammography from December 2019 to April 2024 at Hospital Santa Casa de Porto Alegre. All mammograms extracted in digital imaging and communications in medicine (DICOM) format were anonymized and processed by the Mirai algorithm to generate risk scores. Predictive performance was evaluated using discrimination metrics, such as C-index and area under the curve (AUC), as well as threshold analyses (F1-score, Youden's J) to estimate cancer risk. Mirai obtained a C-index of 0.76 (95% CI: 0.72–0.80) and an AUC of 0.81. The analysis further evaluated the F1-score and Youden's J statistic in an attempt to establish risk thresholds for cancer development. The results suggest that the Mirai model holds promise as a valuable tool for breast cancer detection, particularly for early identification of high-risk patients.
1 January 2026 in Journal of Cachexia, Sarcopenia and Muscle
Background: Bariatric surgery is an effective treatment for obesity but induces substantial muscle loss, potentially leading to sarcopenia. Omega‐3 fatty acids have been associated with improved muscle metabolism, but their effect in the postoperative period of bariatric surgery remains unclear. Methods: A triple‐blind randomized clinical trial following CONSORT guidelines. Patients undergoing bariatric surgery were randomly assigned to receive omega‐3 supplementation (2000 mg/day of EPA + DHA) or placebo (sunflower oil) for 90 days, including 15 days preoperatively and 75 days postoperatively. Assessments were performed at baseline, 45 days and 105 days after the start of supplementation. Outcomes included skeletal muscle mass (bioelectrical impedance [BIA]), handgrip strength (HGS) and functional performance (timed up and go [TUG] test). Results: Fifty‐eight patients were randomized (81% women; mean age 38.2 ± 9.9 years; mean body mass index [BMI]: 41.1 ± 4.6 kg/m 2 ). At baseline, intervention and control groups were comparable in weight (112.7 ± 19.1 vs. 113.0 ± 17.9 kg; p = 0.946), muscle mass (33.5 ± 7.5 vs. 32.5 ± 7.3 kg; p = 0.603), HGS (33.3 ± 9.6 vs. 35.4 ± 10.2 kgf; p = 0.428) and TUG (8.7 ± 3.0 vs. 8.7 ± 1.8 s; p = 0.912). Between baseline and 105 days, muscle mass decreased significantly in both groups (−3.1 ± 0.3 kg; −2.2 ± 0.5 kg; both p < 0.001), without interaction between groups ( p = 0.300). HGS remained stable (Δ −0.8 to +2.3 kgf; all p ≥ 0.364), and TUG performance did not change significantly (Δ 0.0–1.1 s; all p ≥ 0.106). Weight loss was marked in both groups (−19.3 ± 1.9 vs. −17.7 ± 2.1 kg; both p < 0.001). The incidence of gastrointestinal symptoms ≥ 3 times/week was similar (34.5% vs. 13.6% at 45 days; p = 0.114). No serious adverse events occurred. Conclusions: Omega‐3 supplementation (2000 mg/day) during the perioperative period of bariatric surgery did not prevent muscle mass loss nor improve muscle strength or functional performance within 105 days of follow‐up. Although the supplementation was safe and well tolerated, it did not demonstrate efficacy in mitigating early sarcopenia‐related outcomes in this population. Trial Registration: ClinicalTrials.gov: NCT06494566